24 papers · ranked by Valyu relevance
Temitayo Ajayi, Seyedmohammadhossein Hosseinian, Andrew J. Schaefer, Clifton D. Fuller
'Clifton D. Fuller'] Chemotherapy is one of the primary modalities of cancer treatment. Chemotherapy drug administration is a complex problem that often requires expensive clinical trials to evaluate potential regimens. One way to alleviate this burden and better inform future trials is to build reliable models for…
Angela M. Jarrett, Danial Faghihi, David A. Hormuth II, Ernesto A. B. F. Lima + 4 more
'Ernesto A. B. F. Lima' 'John Virostko' 'George Biros' 'Debra Patt' 'Thomas E. Yankeelov'] Optimal control theory is branch of mathematics that aims to optimize a solution to a dynamical system. While the concept of using optimal control theory to improve treatment regimens in oncology is not novel, many of the early…
Chase Christenson, Chengyue Wu, David A. Hormuth II, Jingfei Ma + 3 more
'Clinton Yam' 'Gaiane M. Rauch' 'Thomas E. Yankeelov'] Despite advances triple negative breast cancer treatment, ~50% of patients will not achieve a pathological complete response prior to surgery with standard of care neoadjuvant therapy (NAT). We hypothesize that personalized regimens for NAT could significantly…
Mariusz Bodzioch, Piotr Bajger, Urszula Foryś
Chemotherapy remains a widely used cancer treatment. Acquired drug resistance may greatly reduce the efficacy of treatment and means to overcome it are a topic of active discussion among researchers. One of the proposed solutions is to shift the therapeutic paradigm from complete eradication of cancer to maintenance…
Mina Jafari, Behnam Ghavami, Vahid Sattari-Naeini
— The problem of chemotherapy treatment optimization can be defined in order to minimize the size of the tumor without endangering the patient's health; therefore, chemotherapy requires to achieve a number of objectives, simultaneously. For this reason, the optimization problem turns to a multiobjective problem. In…
Trang Le, Sumeyye Su, Leili Shahriyari, Frédéric Lézot
Simple Summary Osteosarcoma is a rare type of cancer with poor prognoses. However, to the best of our knowledge, there are no mathematical models that study the impact of chemotherapy treatments on the osteosarcoma microenvironment. In this study, we developed a data driven mathematical model to analyze the dynamics of…
M. Giles, P.K. Newton
We describe a Q-learning approach to optimized chemotherapy dose scheduling in a stochastic finite-cell Markov process that models tumor cell natural selection dynamics. The three competing subpopulations comprising our virtual tumor are a chemo-sensitive population (S), and two chemo-resistant populations, R_1_ and…
Robin Schmucker, Gabriele Farina, James Faeder, Fabian Fröhlich + 2 more
The design of efficient combination therapies is a difficult key challenge in the treatment of complex diseases such as cancers. The large heterogeneity of cancers and the large number of available drugs renders exhaustive in vivo or even in vitro investigation of possible treatments impractical. In recent years…
Sibylle Schirm, Christoph Engel, Sibylle Loibl, Markus Loeffler + 1 more
'Markus Scholz'] Purpose Although G-CSF is widely used to prevent or ameliorate leukopenia during cytotoxic chemotherapies, its optimal use is still under debate and depends on many therapy parameters such as dosing and timing of cytotoxic drugs and G-CSF, G-CSF pharmaceuticals used and individual risk factors of…
Shu Zhu, Dhruba Deb, Tal Danino
Predicting patient responses to chemotherapy regimens is a major challenge in cancer treatment. To do this requires quantitative mathematical models to predict optimal dose and frequency for a particular drug, and experimental model systems such as three-dimensional organoids that accurately recapitulate the tumor…
Kai Gong, Tong Lu, Xu Wang, Xinggao Liu
Cytotoxic chemotherapy and immune checkpoint inhibitors (ICIs) have transformed the management of advanced cancers, yet durable responses remain restricted to subsets of patients and strongly depend on the tumor immune microenvironment (TIME). Distinct “hot” and “cold” TIMEs differ in pre-existing effector T-cell…
Ioannis Lampropoulos, Yorgos Psarellis, Michail Kavousanakis
Designing combination cancer therapies requires choosing not only which agents to combine but also their relative doses and timing decisions that critically shape the trade-off between efficacy and toxicity. High-fidelity mechanistic models of tumor growth, formulated as systems of coupled PDEs, can in principle…
Otto I. Pulkkinen, Prson Gautam, Ville Mustonen, Tero Aittokallio
Combinatorial therapies are required to treat patients with advanced cancers that have become resistant to monotherapies through rewiring of redundant pathways. Due to a massive number of potential drug combinations, there is a need for systematic approaches to identify safe and effective combinations for each patient…
Sébastien Benzekry, Philip Hahnfeldt
Although optimal control theory has been used for the theoretical study of anticancerous drugs scheduling optimization, with the aim of reducing the primary tumor volume, the effect on metastases is often ignored. Here, we use a previously published model for metastatic development to define an optimal control problem…
S. Mahmoodifar, P.K. Newton
We introduce a mathematical model of the cancer-immunity cycle and use it to test several hypotheses regarding the combination, timing, and optimization associated with chemotherapy and immunotherapy dosing schedules in the context of competition and selection pressure. A key conceptual idea is the value of…
Jeffrey West, Paul K. Newton
We extend classical tumor regression models, such as the Norton-Simon hypothesis, from instantaneous regression rates (i.e. the derivative) to the cumulative effect (i.e. the integral) over one (or many) cycles of chemotherapy. To achieve this end, we use a stochastic Moran process model of tumor cell kinetics, coupled…
Qie He, Junfeng Zhu, David Dingli, Jasmine Foo + 1 more
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations that preexist treatment…
Yosi Gilad, Gary Gellerman, David M. Lonard, Bert W. O’Malley
Simple Summary Chemotherapy is a key modality in today’s practice of clinical oncology. The potential for systemic treatment of cancer patients with cytotoxic agents was discovered in the mid 20th century and its major shortcomings namely, off target toxicity and resistance to treatment, were apparent from the very…
Authors not listed
Therapeutic drug monitoring enables personalized cancer medicine by dosing patients with chemotherapy based on the patient’s own unique rate of drug clearance and metabolic degradation. These rates significantly influence the plasma concentration which influences patient outcomes. This is especially true for the…
Ryan Miller, Sebastian Muraru, Ana Belén Malpartida, Josh Low + 7 more
Within the next twenty years, the number of cancer patients is expected to rise by 70%. Current cancer treatments still face several limitations, such as severe side effects and a high incidence of disease recurrence. Drug combination therapies are a promising strategy to achieve higher therapeutic effects while…
Authors not listed
This conceptual framework proposes an out-of-the-box approach to innovate non-biological drugs that surpass biologics by 200-fold in efficacy and safety for cancer treatment. Integrating advanced paradigms from physics, chemistry, medicine, biology, engineering, and materials science, we delineate a multi-dimensional…
Liping Zhang, Ben Zhong Tang, Zheng Zhao, Yu Xiong + 8 more
Targeted and controllable drug release at lesion sites with the aid of visual navigation in real-time is of great significance for precise theranostics of cancers. Benefiting from the marvellous features (e.g. bright emission and phototheranostic effect in aggregates) of aggregation-induced emission (AIE) materials…
Authors not listed
Chemotherapy plays a crucial role in clinical cancer treatment. However, it is confronted with dire challenges in achieving high specificity due to their indiscriminate interaction with both tumor cells and normal cells. Herein, we develop a photodynamic therapy (PDT)-accelerated supramolecular nanomaterials based on…
Authors not listed
While metallodrugs have been known for decades, developing new effective formulations still remains a challenge, underscoring the need for new tools to assist identification of potent metal-containing anticancer agents. In this work, we developed a straightforward data-driven approach to predict cytotoxicity of metal…